Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...
Investor's Business Daily on MSN5d
How BioNTech, Up 26% Over Four Days, Is Riding Summit's Coattails To A RecoveryBioNTech stock has climbed 25% over four days as the German biotech rides a round of cancer treatment success from Summit ...
Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...
Summit Therapeutics and Akeso published results for the Phase III HARMONi-2 trial, which tested ivonescimab, a bispecific ...
Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...
Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback